natgillin/translations-raw huggingface dataset:
throat tightness, nose bleeds
tezanje u grlu, krvarenje iz nosa
throat tightness, nose bleeds;
tezanje u grlu, krvarenje iz nosa
Throat tightness, throat irritation, cough
stezanje u grlu, iritacija grla, kašalj
throat tightness, throat irritation, cough
tezanje u grlu, nadražaj u grlu, kašalj
Thrombin is central to the process of blood clotting.
Trombin je ključan u postupku stvaranja krvnih ugrušaka.
Thrombin is one of the substances involved in the clotting process, and when it attaches to the PAR-1 receptor it causes the platelets to become ‘sticky’, helping the blood clot to form.
Trombin je jedna od tvari uključenih u postupak grušanja i prilikom vezivanja na PAR-1 uzrokuje
Thrombin plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently cross- linked framework that stabilises the thrombus.
Trombin ima središnju ulogu u trombotičkom procesu, djelujući na cijepanje fibrinogena na monomere fibrina i aktivirajući faktor XIII do faktora XIIIa, čime fibrin razvija kovalentno umreženu okosnicu koja stabilizira tromb.
Thrombo- cytopaenia; Anaemia; Leucopenia
trombocitopenija, anemija, leukopenija
Thrombo- cytopeniaa
Trombocito- penijaa
Thrombocyte count
Broj trombocita
thrombocyte count ≥ 100 x 109/l common toxicity criteria (CTC) non-haematological toxicity ≤ Grade 1 (except for alopecia, nausea and vomiting).
broj trombocita ≥ 100 x 109/l nehematološka toksičnost prema općim kriterijima toksičnosti (engl. common toxicity criteria, CTC) ≤ stupnja 1 (osim alopecije, mučnine i povraćanja).
Thrombocythaemia Splenomegaly Lymphadenopathy Hypochromasia
trombocitemija splenomegalija limfadenopatija hipokromija
Thrombocythemia
trombocitopenija
Thrombocythemia (incl. platelet count increased)A
Trombocitemija (uključujući povišeni broj trombocit)A
Thrombocythemia (incl. platelet count increased)A
Trombocitemija (uključujući povišeni broj trombocita)A
Thrombocythemia (incl. platelet count increased)A
Trombocitopenija (uključujući povišeni broj trombocita)A
thrombocyto
trombocitope
Thrombocyto penia, anaemia, lymphadenop athy
trombocitopenija, anemija, limfadenopatija
Thrombocyto penia11
trombocitopenija11
Thrombocyto- penia
trombocitopenij a
Thrombocyto- penia
trombocitopenija
thrombocytopaenia
trombocitopenija
thrombocytopaenia (1.3% vs 1.5%), anaemia (4.0% vs
trombocitopenija (1,3% prema 1,5%), anemija (4,0% prema 3,8%)
Thrombocytopaenia (decrease in
trombocitopenija (smanjen broj
Thrombocytopaenia (decrease in platelets) a, b
trombocitopenija (smanjen broj trombocita) a, b
Thrombocytopaenia occurring after first exposure to a GPIIb/IIIa inhibitor may be explained by the fact that antibodies are naturally present in some normal individuals.
Trombocitopenija koja se javlja nakon prvog izlaganja inhibitoru GPIIb/IIIa može biti objašnjena činjenicom da se takva antitijela prirodno mogu naći u pojedinih, inače zdravih osoba.
Thrombocytopaenia**
trombocitopenija
thrombocytopaenia*, e
trombocitopenija*, e
Thrombocytopaenia, including acute profound thrombocytopaenia, has been observed with eptifibatide administration post-marketing (see section 4.8)
Pri primjeni eptifibatida nakon stavljanja lijeka u promet, zabilježena je trombocitopenija, uključujući akutnu, izraženu trombocitopeniju (vidjeti dio 4.8).
Thrombocytopaenia, including acute profound thrombocytopaenia, has been observed with eptifibatide administration post-marketing (see section 4.8).
Pri primjeni eptifibatida nakon stavljanja lijeka u promet, zabilježena je trombocitopenija, uključujući akutnu, izraženu trombocitopeniju (vidjeti dio 4.8).
Thrombocytopaenia, neutropaenia, and anaemia
Trombocitopenija, neutropenija i anemija
Thrombocytope nia11
trombocitopenija11
Thrombocytopeni a11
trombocitopenija11
Thrombocytopeni a; Leukopenia, Pancytopenia
trombocitopenija; leukopenija, pancitopenija
Thrombocytopeni aa
trombocitopenijaa
Thrombocytopenia
trombocito- penija
Thrombocytopenia
Trombocitopenija11
Thrombocytopenia
tromobocitopenija
Thrombocytopenia (2)
trombocitopenija (2)
Thrombocytopenia (4.2%) (G3/4: 0.7%)
Leukopenija (27,9%) (G3/4: 17,0%)
thrombocytopenia (< 100,000 cells/mm3) prothrombin time > 1.2 times control, or International Normalized Ratio (INR)  2.0 severe hypertension (systolic blood pressure > 200 mm Hg or diastolic blood pressure
trombocitopenijom (< 100 000 stanica/mm3) s protrombinskim vremenom > 1,2 puta u odnosu na kontrolnu vrijednost ili INR ≥ 2,0 s teškom hipertenzijom (sistolički krvni tlak > 200 mm Hg ili dijastolički krvni tlak
thrombocytopenia (< 100,000 cells/mm3) prothrombin time > 1.2 times control, or International Normalized Ratio (INR)  2.0 severe hypertension (systolic blood pressure > 200 mm Hg or diastolic blood pressure
trombocitopenijom (< 100000 stanica/mm3) s protrombinskim vremenom > 1,2 puta u odnosu na kontrolnu vrijednost ili INR ≥ 2,0 s teškom hipertenzijom (sistolički krvni tlak > 200 mm Hg ili dijastolički krvni tlak
Thrombocytopenia (< 80 x 109/l), anaemia (haemoglobin < 4.5 g/dl)3
trombocitopenija (< 80 x 109/l), anemija (hemoglobin < 4,5 g/dl)3
Thrombocytopenia (G4: 0.2%)
trombocitopenija (G4: 0,2%)
Thrombocytopenia (in some cases reversible platelet counts less than 5000 mm3).
Trombocitopenija (u nekim slučajevima broj trombocita reverzibilno se spustio na manje od 5000 mm³).
Thrombocytopenia (low level of blood platelets).
Trombocitopenija (niske razine trombocita u krvi)
Thrombocytopenia (low level of blood platelets).
Trombocitopenija (niske razine trombocita u krvi).
Thrombocytopenia (low number of blood platelets)
Trombocitopenija (smanjen broj krvnih pločica)
Thrombocytopenia (low number of platelets, which are cells that help blood to clot).
Trombocitopenija (smanjen broj trombocita, stanica koje pomažu u zgrušavanju krvi).
Thrombocytopenia (some very rare cases were severe with platelet counts less than 5,000 per mm3).
Trombocitopenija (vrlo rijetki slučajevi su bili ozbiljni, u kojima se broj trombocita spustio na manje od 5000 po mm3)
Thrombocytopenia (some very rare cases were severe with platelet counts less than 5.000 per mm3).
Trombocitopenija (vrlo rijetki slučajevi su bili ozbiljni, u kojima se broj trombocita spustio na manje od 5000 po mm3)
Thrombocytopenia (very common).
Trombocitopenija (vrlo često).
Thrombocytopenia a
trombocitopenija
Thrombocytopenia Anaemia
trombocitopenija anemija
Thrombocytopenia Anaemia
trombocitopenija, anemija
Thrombocytopenia and Neutropenia
Trombocitopenija i neutropenija
thrombocytopenia bone disease after exclusion of other causes such as Vitamin D deficiency hepatomegaly or splenomegaly
trombocitopeniju bolest kostiju, nakon isključenja drugih uzroka kao što je nedostatak vitamina D hepatomegaliju ili splenomegaliju
Thrombocytopenia f
trombocitopenijaf
Thrombocytopenia Febrile neutropenia Anaemia Pancytopenia Granulocytopenia
Trombocitopenija Febrilna neutropenija Anemija Pancitopenija Granulocitopenija
Thrombocytopenia has been reported commonly in patients receiving filgrastim.
U bolesnika koji primaju filgrastim često je zabilježena trombocitopenija.
Thrombocytopenia has been reported in patients treated with the ZALTRAP/FOLFIRI regimen.
U bolesnika liječenih protokolom ZALTRAP/FOLFIRI prijavljena je trombocitopenija.
Thrombocytopenia has been reported very commonly in patients receiving filgrastim.
Trombocitopenija je prijavljena vrlo često u bolesnika koji primaju filgrastim.
Thrombocytopenia has been reported very commonly in patients receiving filgrastim.
U bolesnika koji primaju filgrastim vrlo je često zabilježena trombocitopenija.
Thrombocytopenia has been reported very commonly in patients receiving filgrastim.
U bolesnika koji su primali filgrastim vrlo je često bila zabilježena trombocitopenija.
Thrombocytopenia in patients with a positive in-vitro aggregation test in the presence of enoxaparin,
Trombocitopenija u bolesnika s pozitivnim testom agregacije trombocita u prisutnosti enoksaparina in vitro
Thrombocytopenia in patients with a positive in-vitro aggregation test in the presence of enoxaparin,
Trombocitopenija u bolesnika s pozitivnim testom agregacije trombocita u prisutnosti enoksaparina in vitro,
Thrombocytopenia Leukocytosis
trombocitopenija leukocitoza
Thrombocytopenia Lymphadenitis
trombocitopenija limfadenitis
Thrombocytopenia may persist, fluctuate or be transient.
Trombocitopenija može biti trajna, fluktuirajuća ili prolazna.
Thrombocytopenia Neutropenia Anaemia Lymphopenia
Trombocitopenija Neutropenija Anemija Limfopenija
Thrombocytopenia occurred in 27.0% of patients who received Pom + LD-Dex, and 26.8% of patients who received HD-Dex.
Trombocitopenija je nastala u 27,0% bolesnika koji su primali Pom + LD-Dex te 26,8% bolesnika koji su primali HD-Dex.
Thrombocytopenia occurred in 27.0% of relapsed and refractory multiple myeloma patients who received Pom + LD-Dex, and 26.8% of patients who received HD-Dex.
Trombocitopenija se pojavila u 27,0 % bolesnika s recidivirajućim i refraktornim multiplim mijelomom koji su primili Pom + LD- Dex i 26,8 % bolesnika koji su primili HD-Dex.
Thrombocytopenia or coagulation defects;
Trombocitopenija ili poremećaj zgrušavanja;
Thrombocytopenia or decreased platelet counts were reported in 24.9% of patients in clinical studies with trastuzumab emtansine and was the most common adverse reaction leading to treatment discontinuation (2.6%).
Trombocitopenija ili snižen broj trombocita prijavljen je u 24,9% bolesnika u kliničkim ispitivanjima trastuzumab emtanzina i bio je najčešća nuspojava koja je zahtijevala prekid liječenja (2,6%).
Thrombocytopenia or functional platelet defects
trombocitopenija ili funkcionalni defekti trombocita
Thrombocytopenia Splenic rupture
trombocitopenija ruptura slezene
Thrombocytopenia typically occurs between the 5th and the 21st day following the beginning of treatment with enoxaparin sodium.
Trombocitopenija se tipično javlja između 5. i 21. dana nakon početka liječenja enoksaparin-natrijem.
Thrombocytopenia typically occurs between the 5th and the 21st day following the beginning of treatment with enoxaparin sodium.
Trombocitopenija se tipično javlja između 5. i 21. dana nakon početka liječenja enoksaparinnatrijem.
Thrombocytopenia was reported in approximately 40% of subjects in clinical studies with Kyprolis and approximately 20% of subjects had grade ≥ 3 events.
U kliničkim ispitivanjima lijeka Kyprolis trombocitopenija je prijavljena u otprilike 40% ispitanika, a otprilike 20% ispitanika imalo je događaj 3. ili višeg stupnja.
Thrombocytopenia#
trombocitopenija#
Thrombocytopenia*
trombocitopenija
Thrombocytopenia*, coagulopathy*.
Trombocitopenija*, koagulopatija
Thrombocytopenia*, Febrile neutropenia, Neutropenia*, Leukopenia*, Anaemia*, Lymphopenia*
Trombocitopenija*, febrilna neutropenija, neutropenija*, leukopenija*, anemija*, limfopenija
Thrombocytopenia*, Neutropenia*, Anaemia*
trombocitopenija *, neutropenija *, anemija
thrombocytopenia,
trombocitopenija,
Thrombocytopenia,
trombocitopenija, leukopenija, eozinofilija
Thrombocytopenia, Anaemia
trombocitopenija, anemija
Thrombocytopenia, anaemia and leukopenia
trombocitopenija, anemija i leukopenija
thrombocytopenia, anaemia, leukopenia
febrilna neutropenija, trombocitopenija, anemija, leukopenija
Thrombocytopenia, eosinophilia
Trombocitopenija, eozinofilija
Thrombocytopenia, including grade 3 or 4 adverse reactions, has been reported in multiple myeloma patients receiving MPT.
U bolesnika s multiplim mijelomom koji su primali MPT (melfalan, prednizon, talidomid), prijavljena je trombocitopenija uključujući nuspojave 3. ili 4. stupnja.
Thrombocytopenia, leucopenia, eosinophilia
trombocitopenija, leukopenija, eozinofilija
Thrombocytopenia, Leukocytopenia, Neutropenia, Anaemia*
trombocitopenija, leukocitopenija, neutropenija, anemija
thrombocytopenia, leukopenia, anaemia, eosinophilia,
trombocitopenija, leukopenija, anemija, eozinofilija,
thrombocytopenia, leukopenia, leukocytosis, haemorrhagic diathesis
trombocitopenija, leukopenija, leukocitoza, hemoragijska dijateza
thrombocytopenia, neutropenia (blood disorders)
thrombocitopenija, neutropenija (krvni poremećaji)
thrombocytopenia, neutropenia (blood disorders)
trombocitopenija, neutropenija (krvni poremećaji)
thrombocytopenia, neutropenia, anaemia, leukopenia
trombocitopenija, neutropenija, anemija, leukopenija
thrombocytopenia, neutropenia, leukocytosis, polycythaemia, lymphopenia
trombocitopenija, neutropenija, leukocitoza, policitemija, limfopenija
Thrombocytopenia, neutropenia, leukopenia, lymphopenia
Trombocitopenija, neutropenija, leukopenija, limfopenija
Thrombocytopenia, or decreased platelet counts, was commonly reported with trastuzumab emtansine and was the most common adverse reaction leading to treatment discontinuation (see section 4.8).
Trombocitopenija, ili smanjen broj trombocita, često je prijavljena kod primjene trastuzumab emtanzina te je bila najčešća nuspojava koja je zahtijevala prekid liječenja (vidjeti dio 4.8).
Thrombocytopenia, purpura, leukopenia, anemia, methemoglobinemia, agranulocytosis
Trombocitopenija, purpura, leukopenija, anemija, methemoglobinemija, agranulocitoza
Thrombocytopenia, thrombocytopenic purpura
trombocitopenija, trombocitopenična purpura
Thrombocytopenia.
trombocitopenija
Thrombocytopenia1
Trombocitopenija
Thrombocytopenia11
Trombocitopenija
Thrombocytopenia11
trombocitopenija11
Thrombocytopenia:
Trombocitopenija:
Thrombocytopenia: Severe (platelets less than 25 x 109/l) in 25 % of patients (8 % of courses); moderate (platelets between 25.0 and 50.0 x 109/l) in 25 % of patients (15 % of courses).
Trombocitopenija: teška trombocitopenija (broj trombocita < 25 x 109/l) zabilježena je u 25% bolesnika (8% ciklusa), a umjerena (broj trombocita između 25,0 i 50,0 x 109/l) u 25% bolesnika (15% ciklusa).
Thrombocytopenia: Severe (platelets less than 25 x 109/l) in 25 % of patients (8 % of courses); moderate (platelets between 25.0 and 50.0 x 109/l) in 25 % of patients (15 % of courses).
Trombocitopenija: Teška trombocitopenija (broj trombocita <25,0 x 109/l) zabilježena je u 25% bolesnika (8% ciklusa), a umjerena (broj trombocita između 25,0 i 50,0 x 109/l) u 25% bolesnika (15% ciklusa).
Thrombocytopenia: Severe (platelets less than 25 x 109/l) in 25 % of patients (8 % of courses); moderate (platelets between 25.0 and 50.0 x 109/l) in 25 % of patients (15 % of courses).
Trombocitopenija: Teška trombocitopenija (broj trombocita manji od 25,0 x 109/l) zabilježena je u 25% bolesnika (8% ciklusa), a umjerena (broj trombocita između 25,0 i 50,0 x 109/l) u 25% bolesnika (15% ciklusa).
Thrombocytopenia: Severe (platelets less than 25 x 109/l) in 25 % of patients (8 % of courses); moderate (platelets between 25.0 and 50.0 x 109/l) in 25 % of patients (15 % of courses).
Trombocitopenija: Teška trombocitopenija (broj trombocita  25 x 109/l) zabilježena je u 25% bolesnika (8% ciklusa), a umjerena (broj trombocita između 25,0 i 50,0 x 109/l) u 25% bolesnika (15% ciklusa).
Thrombocytopenia: Severe (platelets less than 25 x 109/l) in 25 % of patients (8 % of courses); moderate (platelets between 25.0 and 50.0 x 109/l) in 25% of patients (15 % of courses).
Trombocitopenija: Teška trombocitopenija (broj trombocita  25 x 109/l) zabilježena je u 25% bolesnika (8% ciklusa), a umjerena (broj trombocita između 25,0 i 50,0 x 109/l) u 25% bolesnika (15% ciklusa).
Thrombocytopenia: Severe thrombocytopenia (Grade 4 - platelets less than 10 x 109/l) occurred in 6 % of patients in 2 % of courses.
Trombocitopenija: Teška trombocitopenija (Stupanj 4 - trombociti  10 x 109/l) zabilježena je u 6% bolesnika, u 2% ciklusa.
Thrombocytopenia; Leukopenia, Pancytopenia
trombocitopenij a; leukopenija, pancitopenija
Thrombocytopeniaa
koštanog
Thrombocytopeniaa
trombocitopenija
Thrombocytopeniaa
trombocitopenijaa
Thrombocytopeniaa Leukocytosisa
Trombocitopenij aa leukocitozaa
Thrombocytopeniaa Leukocytosisa
Trombocitopenijaa Leukocitozaa
Thrombocytopeniab
Trombocitopenijab
thrombocytopeniab, lymphopeniab
trombocitopenijab, limfopenijab
thrombocytopenic
trombocitopenična
Thrombocytosis
trombo- citopenija
Thrombocytosis
trombocitoza
Thrombocytosis (see section 4.4)
trombocitoza (vidjeti dio 4.4)
Thromboembo lism (including pulmonary embolism and deep vein thrombosis) (see section 4.4)
tromboembolija (uključujući plućnu emboliju i duboku vensku trombozu) (vidjeti dio 4.4)
Thromboemboli sm (including pulmonary embolism and deep vein thrombosis) (see section 4.4)
tromboembolija (uključujući plućnu emboliju i duboku vensku trombozu) (vidjeti dio 4.4)
thromboembolic
Vrlo rijetko
thromboembolic and ischaemic events, vascular hypotensive disorders, haemorrhage, peripheral vascular disorders
tromboembolijski i ishemijski događaji, krvožilni hipotenzivni poremećaji, krvarenja, periferni krvožilni poremećaji
Thromboembolic complications may occur if the preparation is applied intravascularly (see section 4.4).
Tromboembolijske komplikacije mogu se dogoditi ako se lijek primijeni intravaskularno (vidjeti dio 4.4).
Thromboembolic events
Tromboembolije
Thromboembolic events ITP patients
Tromboembolijski događaji Bolesnici s ITP-om
Thromboembolic events Tabulated list of adverse reactions
tromboembolijski događaji Tablični prikaz nuspojava
Thromboembolic events, including pulmonary embolism
Tromboembolijski događaji, uključujući plućnu emboliju
Thromboembolic events: In patients with VWD, there is a risk of occurrence of thromboembolic events, particularly in patients with known clinical or laboratory risk factors.
Tromboembolijski događaji: U bolesnika s von Willebrandovom bolešću postoji rizik od pojave tromboembolijskih događaja posebice u bolesnika s poznatim kliničkim ili laboratorijskim čimbenicima rizika.
Thromboembolic reactions such as myocardial infarction (tight band around the chest with feeling like your heart is beating too fast), stroke (muscle weakness in the face, arm, or leg, trouble speaking or understanding others who are speaking), pulmonary embolism (shortness of breath, chest pain and fatigue), deep vein thromboses (pain and swelling in an extremity).
Tromboembolijske reakcije kao što su infarkt miokarda (stezanje u prsima s osjećajem prebrzog rada srca), moždani udar (slabost mišića lica, ruke ili noge, otežan govor ili razumijevanje govora), plućna embolija (nedostatak daha, bol u prsima i umor), duboka venska tromboza (bolovi i oticanje udova).
Thromboembolis m (including
Tromboembolija (uključujući plućnu
Thromboembolis m (including pulmonary embolism and deep vein thrombosis) (see section 4.4)
tromboembolija (uključujući plućnu emboliju i duboku vensku trombozu) (vidjeti dio 4.4)
Thromboembolism
1A2, 2D6, 2C9, 2C19, 3A4).
Thromboembolism
Distribucija
Thromboembolism
Farmakodinamička svojstva
Thromboembolism (including
Tromboembolija (uključujući plućnu
Thromboembolism (including pulmonary
Tromboembolija (uključujući plućnu
Thromboembolism (including pulmonary
tromboembolija (uključujući plućnu emboliju i duboku vensku trombozu)
Thromboembolism (including pulmonary
Ventrikularna
Thromboembolism (pulmonary embolism, deep vein thrombosis)*
Tromboembolija (plućna embolija, duboka venska tromboza)
Thromboembolism (pulmonary embolism, deep vein thrombosis)*
tromboembolije (plućna embolija, duboka venska tromboza)
Thromboembolism may occur very rarely, usually associated with severe OHSS (see section 4.4).
Tromboembolija može nastati vrlo rijetko i obično je povezana s teškim OHSS (vidjeti dio 4.4).
Thromboembolism may occur very rarely, usually associated with severe OHSS (see section 4.4).
Tromboembolija se javlja vrlo rijetko, a obično je praćena teškim OHSS (vidjeti dio 4.4).
Thromboembolism may occur very rarely, usually associated with severe OHSS (see section 4.4).
Tromboembolija se javlja vrlo rijetko, a obično je praćena teškim OHSS-om (vidjeti dio 4.4).
Thromboembolism may occur very rarely, usually associated with severe OHSS (see section 4.4).
Tromboembolija se javlja vrlo rijetko, a obično je praćena teškim sindromom hiperstimulacije jajnika (OHSS) (vidjeti dio 4.4).
Thromboembolism may occur very rarely, usually associated with severe OHSS (see section 4.4).
Tromboembolija se javlja vrlo rijetko, obično u sklopu teškog sindroma hiperstimulacije jajnika (OHSS) (vidjeti dio 4.4).
Thromboembolism, usually associated with severe OHSS (see section 4.4).
tromboembolija, obično povezana s teškim OHSS (vidjeti dio 4.4).
Thromboembolism:
Tromboembolija:
ThromboGenics NV Gaston Geenslaan 1 B-3001 Leuven Belgium
ThromboGenics NV Gaston Geenslaan 1 B-3001 Leuven Belgija
Thrombolytics
Trombolitici
Thrombophlebitis
hipertenzija, petehije,
Thrombophlebitis
tromboflebitis
Thrombophlebitis superficial Thrombosis
Površinski tromboflebitis Tromboza Eritromelalgija
thrombophlebitis, flushing, hot flush, hypertension, hypotension
tromboflebitis, crvenilo uz osjećaj vrućine, navale vrućine, hipertenzija, hipotenzija
thrombophlebitis, lymphangitis
tromboflebitis, limfangitis
Thrombophlebitis^
tromboflebitis^
Thromboprophylaxis is recommended in patients being treated with Kyprolis in combination with dexamethasone or with lenalidomide and dexamethasone, and should be based on an assessment of the patient’s underlying risks and clinical status.
U bolesnika koji se liječe kombinacijom lijeka Kyprolis s deksametazonom ili s lenalidomidom i deksametazonom preporučuje se primjena antitrombotskog profilaktičkog liječenja koje se treba temeljiti na procjeni podležećih rizika i kliničkog statusa pojedinog bolesnika.
Thromboprophylaxis should be considered after careful assessment of a patient's risk factors (including the increased risk of serious bleeding in patients with tumour cavitation or tumour involvement of large central blood vessels).
Tromboprofilaksu je potrebno razmotriti nakon pažljive ocjene bolesnikovih faktora rizika (uključujući povećan rizik od ozbiljnog krvarenja u bolesnika s kavitacijom tumora ili u kojih je tumor zahvatio velike središnje krvne žile).
thrombosis
mjestu infuzije
thrombosis
tromboza
Thrombosis (blood clot) is an uncommon side effect (may affect up to 1 in 100 people) which may result in serious or fatal complications such as heart attack.
Tromboza (krvni ugrušak) je manje česta nuspojava (može zahvatiti do 1 na 100 osoba) koja može uzrokovati ozbiljne ili smrtonosne komplikacije, kao što je srčani udar.
Thrombosis has been reported in FVII deficient patients receiving NovoSeven during surgery but the risk of thrombosis in factor VII deficient patients treated with NovoSeven is unknown (see section 5.1).
Tromboza je prijavljena u bolesnika s nedostatkom FVII koji su primali NovoSeven tijekom operativnog zahvata, ali je rizik pojave tromboze u bolesnika s nedostatkom faktora VII liječenih lijekom NovoSeven nepoznat (vidjeti dio 5.1).
Thrombosis includes coronary artery thrombosis (blood clot in the heart arteries or within a stent being felt as a heart attack which can also be fatal) and/or thrombosis in the catheter, both of which are rare (may affect up to 1 in 1,000 people).
Tromboza uključuje trombozu koronarnih arterija (krvni ugrušak u srčanim arterijama ili unutar stenta što se osjeća kao srčani udar koji također može biti smrtonosan) i/ili trombozu u kateteru, a obje se javljaju rijetko (mogu zahvatiti do 1 na 1000 osoba).
thrombosis) (see
vensku trombozu)
Thrombosis*; Pulmonary embolism*
tromboza*; plućna embolija
Thrombosis*†
tromboza
thrombosis,
tromboza,
Thrombosis/embolism*
Tromboza/embolija
Thrombotic
trombotička
Thrombotic
trombotična
Thrombotic and embolic events Arterial thromboembolic events
Trombotički i embolijski događaji Arterijski tromboembolijski događaji
Thrombotic events can be a risk in this population and this possibility should be carefully weighed against the benefit to be derived from the treatment.
Trombotički događaji mogu predstavljati rizik u toj populaciji pa tu mogućnost treba pažljivo odvagnuti u odnosu na dobrobiti liječenja.